

# CITATION REPORT

List of articles citing

**Beyond monoamines: glutamatergic function in mood disorder**

**DOI: 10.1017/s1092852900010403**  
**CNS Spectrums, 2005, 10, 808-19.**

**Source:** <https://exaly.com/paper-pdf/37936822/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
233	Sleep in mood disorders. <b>2006</b> , 29, 1009-32; abstract ix		100
232	Depression: comfortably numb. <b>2006</b> , 443, 629-31		7
231	Neuroimmune-endocrine crosstalk in schizophrenia and mood disorders. <b>2006</b> , 6, 1017-38		56
230	Recent Strategies for the Development of New Antidepressant Drugs. <b>2006</b> , 41, 23-38		3
229	Enhancement of antidepressant-like effects but not brain-derived neurotrophic factor mRNA expression by the novel N-methyl-D-aspartate receptor antagonist neramexane in mice. <b>2006</b> , 318, 1128-36		23
228	Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice. <b>2006</b> , 319, 254-9		138
227	Increased anterior cingulate/medial prefrontal cortical glutamate and creatine in bipolar depression. <b>2007</b> , 32, 2490-9		183
226	Investigating the dopaminergic synapse in vivo. I. Molecular imaging studies in humans. <b>2007</b> , 18, 439-72		41
225	Elevated spectroscopic glutamate/gamma-amino butyric acid in rats bred for learned helplessness. <b>2007</b> , 18, 1469-73		66
224	Lamotrigine inhibition of rotenone- or 1-methyl-4-phenylpyridinium-induced mitochondrial damage and cell death. <b>2007</b> , 71, 633-40		37
223	Low cerebrospinal fluid glutamate and glycine in refractory affective disorder. <b>2007</b> , 61, 162-6		117
222	Antidepressant-like effects of ceftriaxone in male C57BL/6J mice. <b>2007</b> , 61, 250-2		115
221	Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. <b>2007</b> , 61, 822-5		160
220	Targeting an old mechanism in a new disease-protection of glutamatergic dysfunction in depression. <b>2007</b> , 61, 137-8		20
219	Gliogenesis and glial pathology in depression. <b>2007</b> , 6, 219-33		416
218	The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. <b>2007</b> , 12, 988-1000		474
217	Enhanced anxiety, depressive-like behaviour and impaired recognition memory in mice with reduced expression of the vesicular glutamate transporter 1 (VGLUT1). <b>2007</b> , 25, 281-90		139

216	Which clinical and experimental data link temporal lobe epilepsy with depression?. <b>2007</b> , 103, 2136-52	77
215	Glia mechanisms in mood regulation: a novel model of mood disorders. <b>2007</b> , 191, 55-65	51
214	[Immunological aspects of depressive disorders]. <b>2007</b> , 78, 1261-73	33
213	Mapping of QTLs for oral alcohol self-administration in B6.C and B6.I quasi-congenic RQI strains. <b>2007</b> , 32, 1099-112	17
212	A psychoneuroimmunological perspective to Emil Kraepelins dichotomy: schizophrenia and major depression as inflammatory CNS disorders. <b>2008</b> , 258 Suppl 2, 97-106	93
211	Neurotransmission and bipolar disorder: a systematic family-based association study. <b>2008</b> , 147B, 1270-7	22
210	Major depression: emerging therapeutics. <b>2008</b> , 75, 204-25	37
209	Glutamate and neurotrophic factors in neuronal plasticity and disease. <b>2008</b> , 1144, 97-112	430
208	Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. <b>2008</b> , 7, 426-37	633
207	Early intervention in bipolar disorder, part I: clinical and imaging findings. <b>2008</b> , 2, 122-35	17
206	Novel drugs and therapeutic targets for severe mood disorders. <b>2008</b> , 33, 2080-92	171
205	The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. <b>2008</b> , 63, 1103-10	218
204	Abnormal glutamatergic neurotransmission and neuronal-glia interactions in acute mania. <b>2008</b> , 64, 718-726	210
203	Chapter 4.4 The glutamatergic system as a potential therapeutic target for the treatment of anxiety disorders. <b>2008</b> , 17, 269-301	7
202	The Medical Basis of Psychiatry. <b>2008</b> ,	4
201	Repeated administration of imipramine attenuates glutamatergic transmission in rat frontal cortex. <b>2008</b> , 153, 789-95	52
200	Lithium effects on brain glutamatergic and GABAergic systems of healthy volunteers as measured by proton magnetic resonance spectroscopy. <b>2008</b> , 32, 249-56	33
199	A systematic review of off-label uses of memantine for psychiatric disorders. <b>2008</b> , 32, 1362-74	79

198	Riluzole in the treatment of mood and anxiety disorders. <b>2008</b> , 22, 761-86	121
197	mGlu5 receptor antagonists and their therapeutic potential. <b>2008</b> , 18, 123-142	51
196	Differential effects of citalopram and reboxetine on cortical Glx measured with proton MR spectroscopy. <b>2008</b> , 22, 473-6	35
195	Metabolomics: A Global Biochemical Approach to the Discovery of Biomarkers for Psychiatric Disorders. <b>2008</b> , 129-162	1
194	AMPA receptor subunit 1 (GluR-A) knockout mice model the glutamate hypothesis of depression. <b>2008</b> , 22, 3129-34	114
193	Genetic markers within glutamate receptors associated with antidepressant treatment-emergent suicidal ideation. <b>2008</b> , 165, 917-8	31
192	COX-2 inhibition in schizophrenia and major depression. <b>2008</b> , 14, 1452-65	84
191	Neurobiology of depression, fibromyalgia and neuropathic pain. <b>2009</b> , 14, 5291-338	227
190	The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. <b>2009</b> , 15, 525-39	132
189	Elevated levels of NR2A and PSD-95 in the lateral amygdala in depression. <b>2009</b> , 12, 143-53	89
188	Decreased glutamate/glutamine levels may mediate cytidine <del>N</del> efficacy in treating bipolar depression: a longitudinal proton magnetic resonance spectroscopy study. <b>2009</b> , 34, 1810-8	53
187	Spectroscopic correlates of antidepressant response to sleep deprivation and light therapy: a 3.0 Tesla study of bipolar depression. <b>2009</b> , 173, 238-42	41
186	Normal metabolite levels in the left dorsolateral prefrontal cortex of unmedicated major depressive disorder patients: a single voxel (1)H spectroscopy study. <b>2009</b> , 174, 177-83	54
185	Targeting glial physiology and glutamate cycling in the treatment of depression. <b>2009</b> , 78, 431-9	68
184	Modulation of group II metabotropic glutamate receptor (mGlu2) elicits common changes in rat and mice sleep-wake architecture. <b>2009</b> , 603, 62-72	51
183	Depression and antidepressants: molecular and cellular aspects. <b>2009</b> , 66, 2985-3008	57
182	Don't be afraid to treat depression in patients with epilepsy!. <b>2009</b> , 119, 75-80	49
181	Eyeblink conditioning anomalies in bipolar disorder suggest cerebellar dysfunction. <b>2009</b> , 11, 19-32	37

180	Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. <b>2009</b> , 11, 523-9	193
179	Genetic variation in the G72 (DAOA) gene affects temporal lobe and amygdala structure in subjects affected by bipolar disorder. <b>2009</b> , 11, 621-7	14
178	Association of markers in the 3Nregion of the GluR5 kainate receptor subunit gene to alcohol dependence. <b>2009</b> , 33, 925-30	52
177	Metabolomics: a global biochemical approach to the study of central nervous system diseases. <b>2009</b> , 34, 173-86	208
176	Glutamate receptors as targets of protein kinase C in the pathophysiology and treatment of animal models of mania. <b>2009</b> , 56, 47-55	82
175	Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. <b>2009</b> , 33, 70-5	276
174	Current investigational drugs for major depression. <b>2009</b> , 18, 767-88	79
173	Safety and Tolerability of Acamprosate in Alcohol-dependent Individuals With Bipolar Disorder. <b>2009</b> , 8, 33-38	7
172	Antidepressant effects of estrogens: a basic approximation. <b>2010</b> , 21, 451-64	42
171	Neurotransmitter Systems in Bipolar Disorder. <b>2010</b> , 210-227	3
170	The involvement of NMDA and AMPA receptors in the mechanism of antidepressant-like action of zinc in the forced swim test. <b>2010</b> , 39, 205-17	68
169	Sigma receptors: potential targets for a new class of antidepressant drug. <b>2010</b> , 127, 271-82	92
168	Brain glutamatergic characteristics of pediatric offspring of parents with bipolar disorder. <b>2010</b> , 182, 165-71	24
167	Determination of L-serine-O-phosphate in rat and mouse brain tissue using high-performance liquid chromatography and fluorimetric detection. <b>2010</b> , 405, 260-2	5
166	An update on the role of glutamate in the pathophysiology of depression. <b>2010</b> , 122, 192-210	66
165	Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. <b>2010</b> , 15, 501-11	328
164	Histology. 14-32	
163	Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole. <b>2010</b> , 35, 834-46	138

162	Glutamatergic and resting-state functional connectivity correlates of severity in major depression - the role of pregenual anterior cingulate cortex and anterior insula. <b>2010</b> , 4,	128
161	Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. <b>2010</b> , 68, 785-94	363
160	Therapeutic options for treatment-resistant depression. <b>2010</b> , 24, 131-61	141
159	Glutamatergic modulatory therapy for Tourette syndrome. <b>2010</b> , 74, 862-7	61
158	Reduced expression of glutamate transporters vGluT1, EAAT2 and EAAT4 in learned helpless rats, an animal model of depression. <b>2010</b> , 58, 465-73	133
157	Structural and synaptic plasticity in stress-related disorders. <b>2011</b> , 22, 535-49	209
156	Cytokines and depression: findings, issues, and treatment implications. <b>2011</b> , 22, 295-302	21
155	Imipramine counteracts corticosterone-induced enhancement of glutamatergic transmission and impairment of long-term potentiation in the rat frontal cortex. <b>2011</b> , 63, 1404-12	10
154	Stressor-induced NMDAR dysfunction as a unifying hypothesis for the aetiology, pathogenesis and comorbidity of clinical depression. <b>2011</b> , 77, 508-28	41
153	Suicidality and epilepsy: a neuropsychobiological perspective. <b>2011</b> , 22, 77-84	38
152	Morphometric post-mortem studies in bipolar disorder: possible association with oxidative stress and apoptosis. <b>2011</b> , 14, 1075-89	81
151	Depression and epilepsy: A bidirectional relation?. <b>2011</b> , 52 Suppl 1, 21-7	141
150	Resting glutamate levels and rapid glutamate transients in the prefrontal cortex of the Flinders Sensitive Line rat: a genetic rodent model of depression. <b>2011</b> , 36, 1769-77	39
149	Ventromedial prefrontal spectroscopic abnormalities over the course of depression: a comparison among first episode, remitted recurrent and chronic patients. <b>2011</b> , 45, 427-34	99
148	Evidence for a key role of the peripheral kynurenine pathway in the modulation of anxiety- and depression-like behaviours in mice: focus on individual differences. <b>2011</b> , 98, 161-8	47
147	Influence of work shift on glutamic acid and gamma-aminobutyric acid (GABA): evaluation with proton magnetic resonance spectroscopy at 3T. <b>2011</b> , 192, 55-9	17
146	Inflammatory biomarkers and depression. <b>2011</b> , 19, 308-18	88
145	Proof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments. <b>2011</b> , 28, 267-81	20

144	The metabotropic glutamate receptor 7 allosteric modulator AMN082: a monoaminergic agent in disguise?. <b>2011</b> , 338, 345-52	87
143	The neurobehavioral pharmacology of ketamine: implications for drug abuse, addiction, and psychiatric disorders. <b>2011</b> , 52, 366-78	35
142	The glutamatergic neurotransmission in the central nervous system. <b>2012</b> , 19, 1269-76	43
141	Increase of hippocampal glutamate after electroconvulsive treatment: a quantitative proton MR spectroscopy study at 9.4 T in an animal model of depression. <b>2012</b> , 13, 447-57	20
140	Manic switch after adjuvant lamotrigine treatment. <b>2012</b> , 2, 129	1
139	Investigational NMDA receptor modulators for depression. <b>2012</b> , 21, 91-102	40
138	Evaluation of behavioral and neurochemical changes induced by ketamine in rats: implications as an animal model of mania. <b>2012</b> , 46, 1569-75	35
137	Genetic association study of individual symptoms in depression. <b>2012</b> , 198, 400-6	30
136	Pathophysiology of mood disorders in temporal lobe epilepsy. <b>2012</b> , 34 Suppl 2, S233-45	31
135	Depression and epilepsy: epidemiologic and neurobiologic perspectives that may explain their high comorbid occurrence. <b>2012</b> , 24, 156-68	202
134	The integrated model of serotonin transporter gene variation (5HTTLPR) and the glial cell transporter in stress vulnerability and depression. <b>2012</b> , 78, 410-4	2
133	Blockade of astrocytic glutamate uptake in the prefrontal cortex induces anhedonia. <b>2012</b> , 37, 2467-75	88
132	Can neurobiological pathogenic mechanisms of depression facilitate the development of seizure disorders?. <b>2012</b> , 11, 1093-102	98
131	Stress- and antidepressant treatment-induced modifications of 5-HT <sub>1A</sub> receptor functions in the rat brain. <b>2012</b> , 64, 1305-15	7
130	Psychopharmacologic treatment of children and adolescents with anxiety disorders. <b>2012</b> , 21, 527-39	42
129	Platelet uptake of GABA and glutamate in patients with bipolar disorder. <b>2012</b> , 14, 301-8	11
128	Developmental nicotine exposure induced alterations in behavior and glutamate receptor function in hippocampus. <b>2012</b> , 69, 829-41	49
127	The mild encephalitis concept for psychiatric disorders revisited in the light of current psychoneuroimmunological findings. <b>2013</b> , 19, 87-101	23

126	A consensus panel review of central nervous system effects of the exposure to low-intensity extremely low-frequency magnetic fields. <b>2013</b> , 6, 469-76	67
125	A critical review of the mechanism of action for the selective serotonin reuptake inhibitors: do these drugs possess anti-inflammatory properties and how relevant is this in the treatment of depression?. <b>2013</b> , 67, 304-17	111
124	Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression. <b>2013</b> , 74, 734-41	103
123	Acute antidepressant treatment differently modulates ERK/MAPK activation in neurons and astrocytes of the adult mouse prefrontal cortex. <b>2013</b> , 232, 161-8	25
122	A systematic review and meta-analysis of proton magnetic resonance spectroscopy and mismatch negativity in bipolar disorder. <b>2013</b> , 23, 1348-63	83
121	The glycolytic enzyme aldolase C is up-regulated in rat forebrain microsomes and in the cerebrospinal fluid after repetitive fluoxetine treatment. <b>2013</b> , 1520, 1-14	14
120	Zinc, magnesium and NMDA receptor alterations in the hippocampus of suicide victims. <i>Journal of Affective Disorders</i> , <b>2013</b> , 151, 924-31	6.6 48
119	Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. <b>2013</b> , 263, 367-77	160
118	Effects of MPEP, a selective metabotropic glutamate mGlu5 ligand, on sleep and wakefulness in the rat. <b>2013</b> , 40, 18-25	11
117	Neurodegeneration, Amyloid and mood disorders: state of the art and future perspectives. <b>2013</b> , 28, 661-71	10
116	Evaluation of anti-epileptic property of <i>Marsilea quadrifolia</i> Linn. in maximal electroshock and pentylenetetrazole-induced rat models of epilepsy. <b>2013</b> , 27, 1707-14	4
115	Glutamine deficiency in the prefrontal cortex increases depressive-like behaviours in male mice. <b>2013</b> , 38, 183-91	54
114	[Role of glutamate transporters in the pathophysiology of major mental illnesses]. <b>2013</b> , 142, 291-6	1
113	Intrathecal lamotrigine attenuates antinociceptive morphine tolerance and suppresses spinal glial cell activation in morphine-tolerant rats. <b>2013</b> , 28, 300-7	8
112	D-serine as a gliotransmitter and its roles in brain development and disease. <b>2013</b> , 7, 39	76
111	Neurobiological Background of Affective Disorders. <b>2013</b> ,	1
110	The self-liking brain: a VBM study on the structural substrate of self-esteem. <b>2014</b> , 9, e86430	23
109	Effect of Ascorbic Acid on Mental Depression Drug Therapy: Clinical Study. <b>2014</b> , 04,	10



108	. <b>2014</b> ,	2
107	Decreased plasma neuroactive amino acids and increased nitric oxide levels in melancholic major depressive disorder. <b>2014</b> , 14, 123	42
106	Inflammation in the Pathogenesis of Depression. <b>2014</b> , 261-288	1
105	Revisiting the monoamine hypothesis of depression: a new perspective. <b>2014</b> , 6, 1-8	22
104	Autoantibodies and depression: evidence for a causal link?. <b>2014</b> , 40, 62-79	32
103	The theory of bipolar disorder as an illness of accelerated aging: implications for clinical care and research. <b>2014</b> , 42, 157-69	105
102	Efficient synthesis of new biheterocyclic 1-(5-hydroxy-5-trifluoromethyl-4,5-dihydropyrazol-1-yl)-3-(6-trifluoromethylpyrimidin-4-yl)-propan-1-ones. <b>2014</b> , 158, 16-20	5
101	Dysfunctional glutamatergic and GABAergic activities in prefrontal cortex of mice in social defeat model of depression. <b>2014</b> , 76, 231-8	87
100	Is depression associated with an increased risk of treatment-resistant epilepsy? Research strategies to investigate this question. <b>2014</b> , 38, 3-7	45
99	A novel analog of olanzapine linked to sarcosinyl moiety (PGW5) demonstrates high efficacy and good safety profile in mouse models of schizophrenia. <b>2014</b> , 24, 425-36	6
98	Immunology of major depression. <b>2014</b> , 21, 123-30	110
97	Characterisation of the antidepressant properties of nitric oxide synthase inhibitors in the olfactory bulbectomised rat model of depression. <b>2014</b> , 24, 1349-61	20
96	Bipolar (Manic Depressive) Disorders. <b>2015</b> , 857-901	1
95	AMPA Receptor-mTOR Activation is Required for the Antidepressant-Like Effects of Sarcosine during the Forced Swim Test in Rats: Insertion of AMPA Receptor may Play a Role. <b>2015</b> , 9, 162	28
94	A Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical Correlates. <b>2015</b> , 13, 324-68	61
93	Preventive Effect of Cecropia pachystachya Against Ketamine-Induced Manic Behavior and Oxidative Stress in Rats. <b>2015</b> , 40, 1421-30	18
92	Early postnatal exposure to lithium in vitro induces changes in AMPAR mEPSCs and vesicular recycling at hippocampal glutamatergic synapses. <b>2015</b> , 40, 339-54	4
91	Investigation of Heschl's gyrus and planum temporale in patients with schizophrenia and bipolar disorder: a proton magnetic resonance spectroscopy study. <b>2015</b> , 161, 202-9	22

90	Dynamic changes in extracellular release of GABA and glutamate in the lateral septum during social play behavior in juvenile rats: Implications for sex-specific regulation of social play behavior. <b>2015</b> , 307, 117-27	38
89	Activation of mTOR dependent signaling pathway is a necessary mechanism of antidepressant-like activity of zinc. <b>2015</b> , 99, 517-26	33
88	Agmatine induces Nrf2 and protects against corticosterone effects in hippocampal neuronal cell line. <b>2015</b> , 51, 1504-19	44
87	Bipolar Disorder. <b>2015</b> , 1275-1291	1
86	Sequential Astrocytic 5-HT <sub>2B</sub> Receptor Stimulation, [Ca <sup>2+</sup> ] <sub>i</sub> Regulation, Glycogenolysis, Glutamate Synthesis, and K(+) Homeostasis are Similar but Not Identical in Learning and Mood Regulation. <b>2015</b> , 9, 67	3
85	Epilepsy, Antiepileptic Drugs, and Aggression: An Evidence-Based Review. <b>2016</b> , 68, 563-602	132
84	Targeted Metabolomic Pathway Analysis and Validation Revealed Glutamatergic Disorder in the Prefrontal Cortex among the Chronic Social Defeat Stress Mice Model of Depression. <b>2016</b> , 15, 3784-3792	54
83	Zinc transporters protein level in postmortem brain of depressed subjects and suicide victims. <b>2016</b> , 83, 220-229	18
82	Epilepsy coexisting with depression. <b>2016</b> , 68, 1084-92	57
81	Experimental drugs for bipolar psychosis. <b>2016</b> , 25, 1371-1375	6
80	Effects of paternal and peripubertal stress on aggression, anxiety, and metabolic alterations in the lateral septum. <b>2016</b> , 26, 357-367	25
79	NMR- and GC/MS-based metabolomics of sulfur mustard exposed individuals: a pilot study. <b>2016</b> , 21, 479-89	14
78	Efficacy and safety of an adjunctive mGlu <sub>2</sub> receptor positive allosteric modulator to a SSRI/SNRI in anxious depression. <b>2016</b> , 67, 66-73	33
77	Density of GFAP-immunoreactive astrocytes is decreased in left hippocampi in major depressive disorder. <b>2016</b> , 316, 209-20	116
76	Atorvastatin and Fluoxetine Prevent Oxidative Stress and Mitochondrial Dysfunction Evoked by Glutamate Toxicity in Hippocampal Slices. <b>2017</b> , 54, 3149-3161	19
75	Linking lipid peroxidation and neuropsychiatric disorders: focus on 4-hydroxy-2-nonenal. <b>2017</b> , 111, 281-293	43
74	Efficacy of off-label augmentation in unipolar depression: A systematic review of the evidence. <b>2017</b> , 27, 423-441	15
73	Acute Amino Acid d-Serine Administration, Similar to Ketamine, Produces Antidepressant-like Effects through Identical Mechanisms. <b>2017</b> , 65, 10792-10803	23

72	Epilepsy as a Network Disorder (1): What can we learn from other network disorders such as autistic spectrum disorder and mood disorders?. <b>2017</b> , 77, 106-113	24
71	Can Neurochemical Changes of Mood Disorders Explain the Increase Risk of Epilepsy or its Worse Seizure Control?. <b>2017</b> , 42, 2071-2076	11
70	Effect of co-administration of memantine and sertraline on the antidepressant-like activity and brain-derived neurotrophic factor (BDNF) levels in the rat brain. <b>2017</b> , 128, 29-33	23
69	Antidepressant-like effects of long-term sarcosine treatment in rats with or without chronic unpredictable stress. <b>2017</b> , 316, 1-10	15
68	Three clinical pearls in the treatment of patients with seizures and comorbid psychiatric disorders. <b>2017</b> , 7, 235-245	2
67	Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson's Disease. <b>2017</b> , 7, 629-634	30
66	A Review of the Conceptualisation and Risk Factors Associated with Treatment-Resistant Depression. <b>2017</b> , 2017, 4176825	28
65	Histology. 14-32	
64	Hyperforin and Miquelianin from St. John's Wort Attenuate Gene Expression in Neuronal Cells After Dexamethasone-Induced Stress. <b>2018</b> , 84, 696-703	3
63	Stress induced neural reorganization: A conceptual framework linking depression and Alzheimer's disease. <b>2018</b> , 85, 136-151	33
62	Clinical Trials of Anti-Inflammatory Treatments of Major Depression. <b>2018</b> , 489-507	2
61	Gamma-Aminobutyric Acid (GABA): Biosynthesis, Role, Commercial Production, and Applications. <b>2018</b> , 57, 413-452	34
60	The psychopharmacology of epilepsy. <b>2019</b> , 165, 207-227	1
59	Neurobiologic properties of mood disorders may have an impact on epilepsy: Should this motivate neurologists to screen for this psychiatric comorbidity in these patients?. <b>2019</b> , 98, 298-301	9
58	Effects of chronic stress on intestinal amino acid pathways. <b>2019</b> , 204, 199-209	8
57	L-alpha-amino adipic acid provokes depression-like behaviour and a stress related increase in dendritic spine density in the pre-limbic cortex and hippocampus in rodents. <b>2019</b> , 362, 90-102	6
56	P2X7 Purinergic Receptor Is Involved in the Pathophysiology of Mania: a Preclinical Study. <b>2020</b> , 57, 1347-1360	1
55	Internalizing symptoms in intractable pediatric epilepsy: Structural and functional brain correlates. <b>2020</b> , 103, 106845	4

54	Opioid receptor modulation of neural circuits in depression: What can be learned from preclinical data?. <b>2020</b> , 108, 658-678		12
53	Mismatch negativity indices and functional outcomes in unipolar and bipolar depression. <i>Scientific Reports</i> , <b>2020</b> , 10, 12831	4-9	5
52	Analysis of the Gut Microbiota and Inflammatory Factors in mGluR5-Knockout Mice. <i>Frontiers in Psychiatry</i> , <b>2020</b> , 11, 335	5	1
51	The potential for metabolomics in the study and treatment of major depressive disorder and related conditions. <b>2020</b> , 17, 309-322		5
50	Research progress on the role of type I vesicular glutamate transporter (VGLUT1) in nervous system diseases. <b>2020</b> , 10, 26		14
49	NMDA Antagonists and Their Role in the Management of Bipolar Disorder: a Review. <b>2020</b> , 7, 76-85		4
48	The neuropsychology of epilepsy and suicide: A review. <b>2020</b> , 54, 101411		1
47	Real-time detection and imaging of exogenous and endogenous Zn in the PC12 cell model of depression with a NIR fluorescent probe. <b>2021</b> , 146, 3971-3976		1
46	Absence seizures and their relationship to depression and anxiety: Evidence for bidirectionality. <b>2021</b> , 62, 1041-1056		2
45	Modulation of Gut-Brain Axis by Probiotics: A Promising Anti-depressant Approach. <b>2021</b> , 19, 990-1006		4
44	Disrupting phosphorylation of Tyr-1070 at GluN2B selectively produces resilience to depression-like behaviors. <b>2021</b> , 36, 109612		1
43	A glutamate concentration-biased allosteric modulator potentiates NMDA-induced ion influx in neurons. <b>2021</b> , 9, e00859		2
42	Depression-like behavior associated with E/I imbalance of mPFC and amygdala without TRPC channels in mice of knockout IL-10 from microglia. <b>2021</b> , 97, 68-78		4
41	Depressive Disorders in Epilepsy. 126-144		1
40	Inflammatory Biomarkers and Depression. <b>2012</b> , 85-95		1
39	4HNE Protein Adducts in Autistic Spectrum Disorders: Rett Syndrome and Autism. <b>2014</b> , 2667-2687		1
38	Dietary and botanical anxiolytics. <b>2012</b> , 18, RA40-8		10
37	Mice lacking NMDA receptors in parvalbumin neurons display normal depression-related behavior and response to antidepressant action of NMDAR antagonists. <b>2014</b> , 9, e83879		54

36	Assessing the neuronal serotonergic target-based antidepressant strategy: impact of in vivo interaction studies and knockout models. <b>2008</b> , 6, 215-34		8
35	Zinc in the Glutamatergic Theory of Depression. <b>2015</b> , 13, 505-13		39
34	Ketamine for the treatment of depression. <i>Journal of Psychosocial Nursing and Mental Health Services</i> , <b>2013</b> , 51, 11-4	1.1	12
33	Effect of the dysbindin gene on antimanic agents in patients with bipolar I disorder. <i>Psychiatry Investigation</i> , <b>2008</b> , 5, 102-5	3.1	4
32	Glutamate-modulating drugs & the treatment of mental disorders. <i>Journal of Psychosocial Nursing and Mental Health Services</i> , <b>2007</b> , 45, 11-4	1.1	2
31	Strategies to Identify Biomarkers for Depression. <b>2008</b> , 299-314		2
30	Neurobiologic Aspects of Late-Life Mood Disorders. <i>Medical Psychiatry</i> , <b>2008</b> , 133-150		
29	Chemical Imaging: Magnetic Resonance Spectroscopy: The Basics. <b>2010</b> , 121-133		
28	Entzündliche Veränderungen als gemeinsame Pathogenese affektiver und schizophrener Erkrankungen. <b>2010</b> , 59-91		
27	Neuroprotective Agents in Mood Disorders: Pathophysiological and Therapeutic Implications. <b>2010</b> , 417-449		
26	References. <b>2010</b> , 335-393		
25	Molecular Genetics of Tourette Syndrome.		
24	Atypical Psychopharmacologic Strategies. 365-397		
23	Inflammatory Biomarkers and Depression. <b>2013</b> , 89-99		
22	Anti-Inflammatory and Immune-Modulatory Therapeutic Approaches in Major Depression. <b>2016</b> , 115-141		
21	Postnatal Development of Glutamate and GABA Transcript Expression in Monkey Visual, Parietal, and Prefrontal Cortices. <i>Cerebral Cortex</i> , <b>2021</b> , 31, 2026-2037	5.1	2
20	Bipolar disorder. <b>2020</b> , 633-652		
19	Mechanisms of Psychiatric Comorbidities in Epilepsy. <i>Current Topics in Behavioral Neurosciences</i> , <b>2021</b> , 1	3.4	0

18	Novel Mechanisms of Drug Treatment in Psychiatry. <b>2008</b> , 519-534		
17	Antidepressant properties of aqueous macerate from <i>Gladiolus dalenii</i> corms. <i>African Journal of Traditional Complementary and Alternative Medicines</i> , <b>2014</b> , 11, 53-61	0.2	4
16	Tyrosine phosphorylation of glutamate receptors by non-receptor tyrosine kinases: roles in depression-like behavior. <i>Neurotransmitter (Houston, Tex)</i> , <b>2016</b> , 3,		8
15	Functional neuroanatomy of mania.. <i>Translational Psychiatry</i> , <b>2022</b> , 12, 29	8.6	1
14	Metabolomics research on the effect of dexamethasone-induced chronic stress in serum of rabbits. <i>Italian Journal of Animal Science</i> , <b>2022</b> , 21, 188-197	2.2	0
13	Hemispheric asymmetry of motor cortex excitability in mood disorders - Evidence from a systematic review and meta-analysis.. <i>Clinical Neurophysiology</i> , <b>2022</b> , 137, 25-37	4.3	0
12	Ischemia-Induced Cognitive Impairment Is Improved via Remyelination and Restoration of Synaptic Density in the Hippocampus after Treatment with COG-Up in a Gerbil Model of Ischemic Stroke.. <i>Veterinary Sciences</i> , <b>2021</b> , 8,	2.4	0
11	Glutamate Function in Anxiety Disorders and OCD: Evidence from Clinical and Translational Studies. <b>2022</b> , 539-570		
10	Glutamatergic System in Depression and Its Role in Neuromodulatory Techniques Optimization.. <i>Frontiers in Psychiatry</i> , <b>2022</b> , 13, 886918	5	1
9	Riluzole regulates pancreatic cancer cell metabolism by suppressing the Wnt-βcatenin pathway. <i>Scientific Reports</i> , <b>2022</b> , 12,	4.9	0
8	Involvement of regulation of the excitation:inhibition functional balance in the mPFC in the antidepressant-anxiolytic effect of YL-IPA08, a novel TSPO ligand. <i>Metabolic Brain Disease</i> ,	3.9	
7	Internal clock variability, mood swings and working memory in bipolar disorder. <i>Journal of Affective Disorders</i> , <b>2022</b> ,	6.6	
6	The use of <i>Rosmarinus officinalis</i> L. essential oil in Alzheimer's patients. <b>2022</b> , 1, 66-96		
5	Comorbid epilepsy and depression pharmacokinetic and pharmacodynamic drug interactions. 13,		0
4	Cyanidin Chloride Improves LPS-Induced Depression-Like Behavior in Mice by Ameliorating Hippocampal Inflammation and Excitotoxicity. <b>2022</b> , 13, 3023-3033		1
3	Metabolomics analysis of plasma samples of patients with fibromyalgia and electromagnetic sensitivity using GC/MS technique. <b>2022</b> , 12,		0
2	Interleukin-4 mitigates anxiety-like behavior and loss of neurons and fiber tracts in limbic structures in a microglial PPAR $\alpha$ -dependent manner after traumatic brain injury. <b>2023</b> , 180, 106078		0
1	Magnesium and Zinc in Bipolar Disorders. <b>2023</b> , 16, 1-14		0

